Armata Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Armata Pharmaceuticals
ARMP Stock  USD 6.28  0.04  0.64%   
Analyzing historical trends in various income statement and balance sheet accounts from Armata Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Armata Pharmaceuticals' valuation are summarized below:
Gross Profit
-21 M
Market Capitalization
227.2 M
Enterprise Value Revenue
148.1376
Revenue
5.1 M
Earnings Share
(1.66)
There are currently one hundred twenty fundamental signals for Armata Pharmaceuticals that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Armata Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/01/2026, Enterprise Value is likely to grow to about 174 M, while Market Cap is likely to drop slightly above 45.3 M.

Armata Pharmaceuticals Total Revenue

4.18 Million

Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 11.3 M or Selling General Administrative of 12.5 M, as well as many indicators such as Price To Sales Ratio of 12.28, Dividend Yield of 0.0175 or Days Sales Outstanding of 80.61. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Armata Stock
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Armata Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets90.8 M86.4 M43.9 M
Slightly volatile
Short and Long Term Debt Total132.8 M126.5 M31.2 M
Slightly volatile
Other Current Liabilities2.1 M4.1 M1.9 M
Slightly volatile
Total Current Liabilities50.7 M48.2 M11.2 M
Slightly volatile
Property Plant And Equipment Net57.7 M54.9 M17.6 M
Slightly volatile
Accounts Payable727.7 K766 K1.4 M
Very volatile
Cash11.2 M9.3 M8.3 M
Slightly volatile
Non Current Assets Total78.9 M75.1 M33.3 M
Slightly volatile
Cash And Short Term Investments11.3 M9.3 M8.3 M
Slightly volatile
Common Stock Shares Outstanding38 M36.2 M32.4 M
Very volatile
Liabilities And Stockholders Equity90.8 M86.4 M43.9 M
Slightly volatile
Non Current Liabilities Total90.5 M86.2 M31.3 M
Slightly volatile
Other Current Assets2.2 M1.3 M1.8 M
Pretty Stable
Other Stockholder Equity254.7 M279.4 M294.5 M
Very volatile
Total Liabilities141.2 M134.5 M42.5 M
Slightly volatile
Property Plant And Equipment Gross71.5 M68.1 M21.4 M
Slightly volatile
Total Current Assets11 M11.3 M10.6 M
Slightly volatile
Intangible Assets13.1 M9.2 M9.8 M
Pretty Stable
Net Receivables974.8 K744 K941.9 K
Slightly volatile
Common Stock Total Equity308.7 K324.9 K6.6 M
Slightly volatile
Short Term Investments7 M11.1 M9.2 M
Slightly volatile
Common Stock343.9 K362 K6.6 M
Slightly volatile
Capital Surpluse245.6 M247.9 M318.8 M
Slightly volatile
Property Plant Equipment4.4 M4.2 M3.1 M
Slightly volatile
Other Liabilities3.6 M3.5 M2.4 M
Slightly volatile
Net Tangible Assets17 M25.7 M20.5 M
Slightly volatile
Net Invested Capital28.7 M46.4 M18.2 M
Slightly volatile
Capital Stock308.6 K362 K303.5 K
Very volatile
Capital Lease Obligations31.6 M32.1 M14.4 M
Slightly volatile
Deferred Long Term Liabilities8.2 M9.2 M10.1 M
Slightly volatile
Long Term Debt55.1 M55.4 M78.9 M
Slightly volatile

Armata Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.3 M704.6 K
Slightly volatile
Selling General Administrative12.5 M13.2 M7.7 M
Slightly volatile
Other Operating Expenses24.9 M47.6 M20.9 M
Slightly volatile
Total Operating Expenses15.5 M13.2 M13.5 M
Slightly volatile
Research Development36.1 M34.4 M13.9 M
Slightly volatile
Selling And Marketing Expenses831.1 K874.8 K504.2 B
Slightly volatile
Interest Income662.1 K697 K4.2 M
Slightly volatile
Reconciled Depreciation1 M1.3 M699.5 K
Slightly volatile

Armata Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11.8 M19.2 M9.3 M
Slightly volatile
Depreciation1.1 M1.3 M637.1 K
Slightly volatile
Capital Expenditures1.4 M1.9 M1.4 M
Slightly volatile
Total Cash From Financing Activities17.6 M35 M18.3 M
Slightly volatile
End Period Cash Flow12 M14.8 M9.4 M
Slightly volatile
Stock Based Compensation1.8 M2.9 M1.7 M
Slightly volatile
Change To Netincome3.9 M4.5 M2.2 M
Slightly volatile
Cash And Cash Equivalents Changes11.3 M10.7 M5.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.2812.92967.8 K
Slightly volatile
Dividend Yield0.01750.01660.0172
Slightly volatile
Days Sales Outstanding80.6152.4855175
Very volatile
Stock Based Compensation To Revenue0.530.55912.4236
Pretty Stable
Capex To Depreciation1.261.41812.4009
Pretty Stable
Sales General And Administrative To Revenue2.182.298.788
Slightly volatile
Research And Ddevelopement To Revenue5.856.653711.9899
Pretty Stable
Capex To Revenue0.450.36320.8744
Pretty Stable
Cash Per Share0.240.2569143
Slightly volatile
Intangibles To Total Assets0.150.1590.4139
Slightly volatile
Current Ratio0.220.23442.6448
Slightly volatile
Receivables Turnover6.616.95435.6178
Pretty Stable
Capex Per Share0.04940.05215.6292
Slightly volatile
Revenue Per Share0.140.143115.7672
Slightly volatile
Interest Debt Per Share3.613.795791.0311
Slightly volatile
Debt To Assets1.541.46370.4063
Slightly volatile
Graham Number1.3 K1.4 K1.6 K
Slightly volatile
Long Term Debt To Capitalization7.857.47422.2944
Slightly volatile
Total Debt To Capitalization1.691.61170.4745
Slightly volatile
Quick Ratio0.220.23442.6556
Slightly volatile
Net Income Per E B T0.960.830.7749
Pretty Stable
Cash Ratio0.180.19262.0331
Slightly volatile
Days Of Sales Outstanding80.6152.4855175
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.381.051.1246
Pretty Stable
Fixed Asset Turnover0.08950.09420.866
Slightly volatile
Debt Ratio1.541.46370.4063
Slightly volatile
Price Sales Ratio12.2812.92967.8 K
Slightly volatile
Asset Turnover0.05690.05990.0295
Slightly volatile

Armata Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap45.3 M66.9 M45.1 M
Slightly volatile

Armata Fundamental Market Drivers

Armata Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Armata Pharmaceuticals Financial Statements

Armata Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-4.8 M-4.6 M
Total Revenue5.2 M4.2 M
Cost Of Revenue34.4 M36.1 M
Stock Based Compensation To Revenue 0.56  0.53 
Sales General And Administrative To Revenue 2.29  2.18 
Research And Ddevelopement To Revenue 6.65  5.85 
Capex To Revenue 0.36  0.45 
Revenue Per Share 0.14  0.14 
Ebit Per Revenue(8.20)(8.61)

Pair Trading with Armata Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Armata Stock

  0.86VINC Vincerx Pharma, CommonPairCorr
  0.82AVH Avita MedicalPairCorr
  0.82VIVS VivoSim Labs, Symbol ChangePairCorr
  0.79VALN Valneva SE ADRPairCorr
  0.78DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY